180 related articles for article (PubMed ID: 32173978)
21. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
22. Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population.
Wu X; Lu W; Jiang C; Zhang D; Zhang W; Cui Y; Zhuo Z; Mei H; Wang Y; Zhang M; Chen S
PLoS One; 2023; 18(5):e0284825. PubMed ID: 37141338
[TBL] [Abstract][Full Text] [Related]
23. Association of ERCC1 polymorphisms (rs3212986 and rs11615) with the risk of head and neck carcinomas based on case-control studies.
Ding YW; Gao X; Ye DX; Liu W; Wu L; Sun HY
Clin Transl Oncol; 2015 Sep; 17(9):710-9. PubMed ID: 26022132
[TBL] [Abstract][Full Text] [Related]
24. Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.
Li Y; Hu P; Cao Y; Wang GY; Wang N; Zhou RM
Biomarkers; 2014 Mar; 19(2):128-34. PubMed ID: 24499239
[TBL] [Abstract][Full Text] [Related]
25. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
Zhang Q; Lv LY; Li BJ; Zhang J; Wei F
Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354
[TBL] [Abstract][Full Text] [Related]
26. Association of single nucleotide polymorphisms of ERCC1 and XPF with colorectal cancer risk and interaction with tobacco use.
Hou R; Liu Y; Feng Y; Sun L; Shu Z; Zhao J; Yang S
Gene; 2014 Sep; 548(1):1-5. PubMed ID: 24861646
[TBL] [Abstract][Full Text] [Related]
27. The polymorphisms of miRNA-binding site in MLH3 and ERCC1 were linked to the risk of colorectal cancer in a case-control study.
Zhang Q; Zheng X; Li X; Sun D; Xue P; Zhang G; Xiao M; Cai Y; Jin C; Yang J; Wu S; Lu X
Cancer Med; 2018 Apr; 7(4):1264-1274. PubMed ID: 29516665
[TBL] [Abstract][Full Text] [Related]
28. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.
Cao ZH; Yin HP; Jiang N; Yu B
Genet Mol Res; 2015 Aug; 14(3):10145-51. PubMed ID: 26345951
[TBL] [Abstract][Full Text] [Related]
29. Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer.
Liu L; Li CH; Jin TF; Xu DY
Genet Mol Res; 2014 Oct; 13(4):8722-8. PubMed ID: 25366763
[TBL] [Abstract][Full Text] [Related]
30. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
31. Polymorphisms in the ERCC1 and XPF genes and risk of breast cancer in a Chinese population.
Yang Z; Fang X; Pei X; Li H
Genet Test Mol Biomarkers; 2013 Sep; 17(9):700-6. PubMed ID: 23909490
[TBL] [Abstract][Full Text] [Related]
32. Relationship between clinical toxicities and ERCC1 rs3212986 and XRCC3 rs861539 polymorphisms in cervical cancer patients.
Soares S; Nogueira A; Coelho A; Assis J; Pereira D; Bravo I; Medeiros R
Int J Biol Markers; 2018 Jan; 33(1):116-123. PubMed ID: 28708208
[TBL] [Abstract][Full Text] [Related]
33. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer.
Kang S; Ju W; Kim JW; Park NH; Song YS; Kim SC; Park SY; Kang SB; Lee HP
Exp Mol Med; 2006 Jun; 38(3):320-4. PubMed ID: 16819291
[TBL] [Abstract][Full Text] [Related]
34. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population.
Li J; Zuo X; Lv X; Kong F; Xu W; Yang S
Tumour Biol; 2014 Aug; 35(8):7569-74. PubMed ID: 24793015
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.
Metzger R; Warnecke-Eberz U; Alakus H; Kütting F; Brabender J; Vallböhmer D; Grimminger PP; Mönig SP; Drebber U; Hölscher AH; Bollschweiler E
J Gastrointest Surg; 2012 Jan; 16(1):26-34; discussion 34. PubMed ID: 21956434
[TBL] [Abstract][Full Text] [Related]
36. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
Steffensen KD; Waldstrøm M; Jeppesen U; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2008; 18(4):702-10. PubMed ID: 17961161
[TBL] [Abstract][Full Text] [Related]
37. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
[TBL] [Abstract][Full Text] [Related]
38. HapMap-based study of a region encompassing ERCC1 and ERCC2 related to lung cancer susceptibility in a Chinese population.
Yin J; Vogel U; Ma Y; Qi R; Wang H; Yue L; Liang D; Wang C; Li X; Song T
Mutat Res; 2011 Aug; 713(1-2):1-7. PubMed ID: 21601580
[TBL] [Abstract][Full Text] [Related]
39. The Contribution of Excision Repair Cross-complementing Group 1 Genotypes to Colorectal Cancer Susceptibility in Taiwan.
Yueh TC; Chou AK; Gong CL; Fu CK; Pei JS; Wu MH; Tsai CW; Chang WS; Hsiao CL; Yen ST; Li HT; Bau DT
Anticancer Res; 2017 May; 37(5):2307-2313. PubMed ID: 28476796
[TBL] [Abstract][Full Text] [Related]
40. ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy.
Palomba G; Atzori F; Budroni M; Ombra M; Cossu A; Sini M; Pusceddu V; Massidda B; Frau B; Notari F; Ionta M; Palmieri G
J Transl Med; 2014 Sep; 12():272. PubMed ID: 25253066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
